Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

23.03.2026

1 Cell
2 J Immunol
1 J Infect
5 J Infect Dis
1 J Virol
1 MMWR Morb Mortal Wkly Rep
1 PLoS Biol
2 PLoS Comput Biol
1 PLoS Med
22 PLoS One
3 Proc Natl Acad Sci U S A
37 Vaccine
1 Virus Res


    Cell

  1. VARGAS-MALDONADO N, Shetty N, Ferreri LM, Pauly MD, et al
    Controlled human influenza infection reveals heterogeneous expulsion of infectious virus into air.
    Cell. 2026 Mar 19:S0092-8674(26)00232-1. doi: 10.1016/j.cell.2026.
    >> Share


    J Immunol

  2. VAHED H, Chentoufi AA, Prakash S, Quadiri A, et al
    CXCL13/CXCR5 chemokine axis promotes antiviral CXCR5+CD19+ B Cells and follicular/effector CXCR5+CD4+ T Cells in the lungs associated with protection from severe and fatal COVID-19 following infection with pathogenic SARS-CoV-2 Delta variant.
    J Immunol. 2026;215:vkag017.
    >> Share

  3. HANSEN MR, Sedney CJ, Xiao S, Prasad DBR, et al
    Adult mice with neonatal-like T cell subsets exhibit increased susceptibility to Bordetella pertussis and influenza infection.
    J Immunol. 2026;215:vkaf361.
    >> Share


    J Infect

  4. LOWA A, Budt M, Balazs A, Sikora V, et al
    Clade 2.3.4.4b H5N1 influenza A virus exhibits high infectivity in human respiratory tract models.
    J Infect. 2026;92:106722.
    >> Share


    J Infect Dis

  5. RAYENS E, Sy LS, Qian L, Ackerson BK, et al
    Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.
    J Infect Dis. 2026;233:e651-e661.
    >> Share

  6. FOLLMANN D, Dang L, Chu E, Fintzi J, et al
    A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.
    J Infect Dis. 2026;233:e646-e650.
    >> Share

  7. KULLBERG RFJ, Appelman B, Galenkamp H, Prins M, et al
    Gut Microbiota Predicts the Risk of Future COVID-19 Hospitalization and Mortality: Insights From the Population-Based HELIUS Study.
    J Infect Dis. 2026;233:e823-e827.
    >> Share

  8. LINHARES ABREU NETTO R, Chen C, Mwangi VI, Padron de Morais CE, et al
    Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization.
    J Infect Dis. 2026;233:498-509.
    >> Share

  9. SMITH C, Curtis K, Bonham A, Boyer S, et al
    Maternal Inflammation Likely Drives Impaired Immune Responses to Respiratory Syncytial Virus in HIV-Exposed Uninfected Infants.
    J Infect Dis. 2025 Sep 24:jiaf493. doi: 10.1093.
    >> Share


    J Virol

  10. LIU B, Yu H, Yan Z, Zou S, et al
    Identification of thermostability-enhancing mutations in H9N2 avian influenza virus hemagglutinin.
    J Virol. 2026 Mar 16:e0016826. doi: 10.1128/jvi.00168.
    >> Share


    MMWR Morb Mortal Wkly Rep

  11. SHAKYA M, Ma KC, Hughes LJ, Smith C, et al
    Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 - Worldwide, November 2024-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:130-137.
    >> Share


    PLoS Biol

  12. YUKSEL M, Mideo N
    Host jumps need not be common just because spillover is.
    PLoS Biol. 2026;24:e3003682.
    >> Share


    PLoS Comput Biol

  13. WANG X
    Bayesian-calibrated global sensitivity analysis for mathematical models using generative AI.
    PLoS Comput Biol. 2026;22:e1013312.
    >> Share

  14. OKADA Y, Nishiura H
    Reconstructing the incidence rate and immune fraction of the population via a single snapshot survey: A case study of COVID-19 in Japan.
    PLoS Comput Biol. 2026;22:e1013990.
    >> Share


    PLoS Med

  15. ABDEL-QADIR H, Bhatt HA, Swayze S, Paterson M, et al
    Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.
    PLoS Med. 2026;23:e1004924.
    >> Share


    PLoS One

  16. MUWONGE H, Namulondo J, Mugenyi L, Nakaseegu J, et al
    Respiratory syncytial virus burden among Ugandan adults aged >/=65 years: A 15-year sentinel surveillance study of prevalence, coinfections, and comorbidities (2010-2025).
    PLoS One. 2026;21:e0333329.
    >> Share

  17. JEONG YM, Kim M, Jeong JY
    Behavior-biological mismatch in metabolic health: Evidence from South Korean adults before, during, and after COVID-19 (KNHANES 2019-2022).
    PLoS One. 2026;21:e0344918.
    >> Share

  18. JACOBSEN V, Vazquez EA, Herrera L, Escalera R, et al
    Development of a survey and worry score to evaluate physician burnout and wellness interventions during COVID-19 in the Rio Grande Valley: A pilot study.
    PLoS One. 2026;21:e0342993.
    >> Share

  19. JEONG YW
    Predictors of non-suicidal self-injury and moderating effects of cognitive emotion regulation strategies in Korean undergraduate students: Secondary data analysis of a cross-sectional survey.
    PLoS One. 2026;21:e0344175.
    >> Share

  20. LEONARD RA, Truesdale M, Brown M, Marsh L, et al
    A randomised controlled feasibility study of the Carers-ID intervention to support the mental health of family carers of people with intellectual disabilities.
    PLoS One. 2026;21:e0345096.
    >> Share

  21. REINER-BENAIM A, Amar S
    Factors associated with patient adherence to medical recommendations during a health crisis.
    PLoS One. 2026;21:e0345375.
    >> Share

  22. WILHITE JA, Altshuler L, D'Angelo AB, Raykov A, et al
    "It makes me feel so much safer": Sexual and gender minority community perspectives on telehealth use and implications for future practice.
    PLoS One. 2026;21:e0345296.
    >> Share

  23. SANKAR S, Anandharaman K, Selvam P, Jayaraman A, et al
    Genomic evolution of SARS-CoV-2 delta variants pre- and post-omicron emergence using alignment-free machine learning models.
    PLoS One. 2026;21:e0345259.
    >> Share

  24. ESPERANCA M, Galvao T, Freitas D, Ferreira JC, et al
    Integrating medical imaging datasets with blockchain wallets: A case study on ARDS-COVID19 patients.
    PLoS One. 2026;21:e0338897.
    >> Share

  25. PHAM ANQ, Smith J, Byers KA, Card KG, et al
    Associations between demographic, clinical, and socioeconomic factors and mental health in long COVID: A clinic-based cross-sectional study.
    PLoS One. 2026;21:e0342516.
    >> Share

  26. SEKI M, Kobayashi Y, Meroc E, Kitano T, et al
    Estimation of Respiratory Syncytial Virus-attributable hospitalizations among older adults in Japan between 2015 and 2018: An administrative health claims database analysis.
    PLoS One. 2026;21:e0344294.
    >> Share

  27. BROCK J, Lux H, Lang S, Winning J, et al
    Health care system resilience - Evaluating the effect of the COVID-19 pandemic on emergency medical service demand in Germany: A case study from the city of Jena.
    PLoS One. 2026;21:e0344992.
    >> Share

  28. GODIA PM, Hadjiconstantinou M, Weyula R, Ememwa U, et al
    Development of a collaborative chronic care model for management of cardiometabolic disease in low- and middle-income countries.
    PLoS One. 2026;21:e0344527.
    >> Share

  29. LASKE MM, Blackman AL, Oda FS, Reed DD, et al
    Risk identification strategies for health pandemics and epidemics on college campuses: A comprehensive analysis of heat maps and behavioral observations.
    PLoS One. 2026;21:e0343811.
    >> Share

  30. HU A, Pang J, Gan X
    Decisions about risk taking: Elaborate dynamics between guests and hosts of peer-to-peer accommodation during COVID-19.
    PLoS One. 2026;21:e0341733.
    >> Share

  31. GETTLER LT, Hoegler Dennis S, Rosenbaum S, Bechayda SA, et al
    Fathers' caregiving time before and after the COVID-19 pandemic.
    PLoS One. 2026;21:e0343636.
    >> Share

  32. MUKENGE EK, Lengo CN, Sumbu BM, Muwonga JM, et al
    Serum levels of immunoglobulin G and M antibodies against SARS-CoV-2 in asymptomatic individuals prior to COVID-19 vaccination in the Democratic Republic of Congo.
    PLoS One. 2026;21:e0343362.
    >> Share

  33. GASVAER KS, Lind PG, Langguth J, Hjorth-Jensen M, et al
    The 5G COVID-19 Digital Wildfire: An evolving network of Twitter contacts to explore phase transition metaphors in viral misinformation.
    PLoS One. 2026;21:e0343661.
    >> Share

  34. ARIANI Y, Gunawan I, Susanto AD, Sutarto R, et al
    Early clinical and laboratory markers associated with post-COVID respiratory syndrome: A retrospective analysis.
    PLoS One. 2026;21:e0344371.
    >> Share

  35. FILAMANT TC, Raherinirina AF, Totohasina A
    Bayesian networks for predicting clinical outcomes in COVID-19 patients: A retrospective study in a resource-limited setting.
    PLoS One. 2026;21:e0343096.
    >> Share

  36. RASUL MG, Khan AR, Alam MA, Ahmed T, et al
    Understanding effectiveness of a low-cost food package for ensuring food security during the COVID-19 at the household level: Difference-in-differences analyses of a quasi-experimental trial in Bangladesh.
    PLoS One. 2026;21:e0344609.
    >> Share

  37. HWANG J
    Navigating COVID-19: Association between public perceptions of preventive measures and delayed or foregone care among young and middle-aged Korean adults in the early phase of the pandemic.
    PLoS One. 2026;21:e0344209.
    >> Share


    Proc Natl Acad Sci U S A

  38. TUNG W, Yuen M, Cai H, Cho H, et al
    Mild SARS-CoV-2 maternal infection in mice induces transient offspring neurodevelopmental aberrance.
    Proc Natl Acad Sci U S A. 2026;123:e2518294123.
    >> Share

  39. MOHLENBERG M, Jorgensen SE, Marije van der Sluis R, Zillinger T, et al
    Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2522111123.
    >> Share

  40. LAU MSY, Metcalf CJE, Liu Z, Grenfell BT, et al
    Toward AI foundation models for epidemics: Promise, challenges, and paths forward.
    Proc Natl Acad Sci U S A. 2026;123:e2526192123.
    >> Share


    Vaccine

  41. ANWER K, Musso L, Lasrado N, Barouch DH, et al
    Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
    Vaccine. 2026;77:128357.
    >> Share

  42. TAL-SINGER R, McCreary G, Luttmann M, Williams S, et al
    Attitudes toward vaccines and antivirals for viral respiratory infections in a survey of US adults with chronic health conditions.
    Vaccine. 2026;77:128384.
    >> Share

  43. DERAZ N, Payne M, See E, Ragavapuram V, et al
    XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.
    Vaccine. 2026;77:128346.
    >> Share

  44. LI R, Vafeiadis M, Shen F, Hou Z, et al
    The role of health beliefs in COVID-19 vaccination acceptance: A Meta-analysis.
    Vaccine. 2026;77:128379.
    >> Share

  45. HUDSON A, Borgetti S, Rick AM, Laurens MB, et al
    Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.
    Vaccine. 2026;77:128380.
    >> Share

  46. SOHN WY, Goody SMG, Reid DW, Edwards DK, et al
    Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines.
    Vaccine. 2026;77:128394.
    >> Share

  47. EKSTROM N, Liedes O, Vara S, Haveri A, et al
    Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals - A 3.5-year follow-up.
    Vaccine. 2026;77:128347.
    >> Share

  48. BOETTIGER DC, Carlson SJ, Adams SR, Tse V, et al
    Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia.
    Vaccine. 2026;77:128395.
    >> Share

  49. WHITAKER JA, Rebolledo PA, Abate G, Babu TM, et al
    The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
    Vaccine. 2026;77:128358.
    >> Share

  50. SANO K, Kato H, Ryo A, Hasegawa H, et al
    Immune response and IgG subclass dynamics following repeated SARS-CoV-2 mRNA vaccination in Japanese healthcare workers.
    Vaccine. 2026;77:128396.
    >> Share

  51. DAVIS M, Shapiro C, Ciarlet M, Adams EM, et al
    A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age.
    Vaccine. 2026;77:128345.
    >> Share

  52. NUZHATH T, Yang Y, Couture MC, Callaghan T, et al
    Modification and validation of the teen vaccine hesitancy scale toward vaccines for adolescents.
    Vaccine. 2026;77:128385.
    >> Share

  53. GOODFELLOW L, Soble A, Malvolti S, Lambach P, et al
    The potential global health impact and net monetary benefit of programmatic use of improved influenza vaccines: a mathematical modelling study.
    Vaccine. 2026;60 Suppl 2:128455.
    >> Share

  54. YE Q, Chen H, Jia B, Chen X, et al
    Uptake and effectiveness of a novel seasonal influenza vaccination campaign for school-age children in the 2023/2024 influenza season in Shanghai, China.
    Vaccine. 2026;79:128478.
    >> Share

  55. HUNG HC, Jheng KW, Cheng HY, Hsieh HC, et al
    Intranasal prime-boost immunization with trivalent influenza virus neuraminidase proteins and conserved HCA2 sequences fused to a circularly permuted E. coli heat-labile enterotoxin B subunit.
    Vaccine. 2026;79:128488.
    >> Share

  56. DE LOOZE F, Essink BJ, van Boxmeer J, Andrade C, et al
    Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies.
    Vaccine. 2026;79:128436.
    >> Share

  57. DEMIRDEN SF, Kimiz-Gebologlu I, Oncel SS
    Comparative evaluation of cell lines and their serum-free adapted derivatives for H1N1 influenza A virus propagation: bridging laboratory research and industrial vaccine production application.
    Vaccine. 2026;79:128489.
    >> Share

  58. HENG F, Magaret CA, Rouphael NG, Branche AR, et al
    The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.
    Vaccine. 2026;76:128348.
    >> Share

  59. FRANCK Z, Hofstraat S, Jonker L, Kragten L, et al
    The evolving landscape of RSV immunization: Current policies and practices across Europe.
    Vaccine. 2026;76:128222.
    >> Share

  60. IMANISHI Y, Iorini M, Wada I, Jwa S, et al
    Child sexual abuse and adult vaccination: Opposing patterns between routine and pandemic vaccines in a Nationwide survey.
    Vaccine. 2026;76:128299.
    >> Share

  61. PARIS L, Domegan L, O'Leary M, Hanrahan M, et al
    Protecting infants from respiratory syncytial virus (RSV) in Ireland: Impact of a national nirsevimab immunisation programme, 2024/2025.
    Vaccine. 2026;76:128344.
    >> Share

  62. MAKI W, Ishitsuka K, Morisaki N, Machida M, et al
    Association of parental vaccination readiness and descriptive norms with childhood vaccination status.
    Vaccine. 2026;76:128337.
    >> Share

  63. OGAWA T, Sunyi J, Kawachi K, Murakami J, et al
    Regulatory approaches for platform-based vaccine development in Japan: Insights from PMDA's experience with COVID-19 and RSV vaccines.
    Vaccine. 2026;76:128315.
    >> Share

  64. STEFKOVICS A, Ligeti AS, Koltai J
    Willingness to vaccinate in a future pandemic. Evidence from a vignette experiment.
    Vaccine. 2026;76:128284.
    >> Share

  65. URIU K, Kaku Y, Kosugi Y, Chen L, et al
    Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.
    Vaccine. 2026;76:128311.
    >> Share

  66. CAO Q, Du S, Yang K, Liu M, et al
    Assessing the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive techniques outcomes: an umbrella review.
    Vaccine. 2026;76:128293.
    >> Share

  67. GREWAL R, Alessandrini J, Wilson SE, Hernandez A, et al
    Human papillomavirus (HPV) vaccine coverage and associated sociodemographic factors among individuals eligible for publicly funded vaccine in Ontario, Canada from 2007 to 2023: A Canadian immunization research network study.
    Vaccine. 2026;76:128303.
    >> Share

  68. OYEDELE T, Park R, Morales K, Jain M, et al
    A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.
    Vaccine. 2026;76:128304.
    >> Share

  69. STEFFENS M, Bolsewicz K, Prokopovich K, Beard F, et al
    Immunisation program managers' experiences of implementing the change from a two dose to a single dose course of HPV vaccination in Australia's school-based program.
    Vaccine. 2026;76:128300.
    >> Share

  70. SMITH EA, Malhame M, Malvolti S, Voss G, et al
    Use cases for pan-sarbecovirus vaccines: a workshop report.
    Vaccine. 2026;76:128312.
    >> Share

  71. ALMEIDA ST, Paulo AC, Simoes AS, Handem S, et al
    Pneumococcal carriage and serotype distribution in Portuguese children six months after the lifting of COVID-19 restrictions: rise in serotype 3 amid stable non-vaccine serotypes.
    Vaccine. 2026;76:128294.
    >> Share

  72. MELAKU T, Gudina EK, Sorensen JB, Draebel TA, et al
    Trends and recovery of routine childhood immunization before, during, and after the COVID-19 pandemic in Ethiopia: A five-year trend analysis.
    Vaccine. 2026;77:128343.
    >> Share

  73. MADLEY-DOWD P, Horne EMF, Hulme WJ, Palmer TM, et al
    Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY.
    Vaccine. 2026 Feb 18:128276. doi: 10.1016/j.vaccine.2026.128276.
    >> Share

  74. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of spontaneous abortion after mRNA COVID-19 vaccination received just prior to or during pregnancy: Complete data from CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;76:128340.
    >> Share

  75. BARBOZA APB, Luna-Muschi A, Faffe D, Borges IC, et al
    Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.
    Vaccine. 2026;77:128354.
    >> Share

  76. CHANDRA LA, Nugroho DB, Thobari JA, Dimaguila GL, et al
    Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review.
    Vaccine. 2026;77:128341.
    >> Share

  77. MORENO MZ, Martin JJP
    Evaluation of the impact of different notification methods for unvaccinated individuals in a ACWY meningococcal vaccination campaign.
    Vaccine. 2026;77:128383.
    >> Share


    Virus Res

  78. XIE C, Zhao Y, Wang B, He T, et al
    Identification of key genes modules linking brain aging signatures and COVID-19-associated cognitive impairment.
    Virus Res. 2026;366:199707.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016